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Abstract
Background: Our aim was to explore the de-addiction properties of Delphinium denudatum Wall.
in morphine dependent rats.
Methods: Charles Foster male albino rats were made morphine dependent by injecting morphine
sulphate in increasing doses twice a day for 7 days. The spontaneous withdrawal signs observed 12
h after the last dose were quantified by the 'counted' and 'checked' signs. The drug (alcoholic
extract of Delphinium denudatum) was administered p.o. in different regimen: a) single dose (700
mg/kg) 10 h before the first dose of morphine, b) single dose (700 mg/kg) 10 h after the last dose
of morphine, c) multiple doses (350 mg/kg) along with morphine twice a day for 7 days.
Result:  Administration of Delphinium denudatum extract caused significant reduction in the
frequency of counted signs as well as the presence of checked signs of morphine withdrawal. The
maximum reduction was observed in regimen 'b' followed by regimen 'c' and 'a'.
Conclusion:  Delphinium denudatum Wall. significantly reduces the aggregate scores for all
parameters in morphine withdrawal syndrome by central action and thus may prove to be an
alternative remedy in morphine de-addiction.
Background
Delphinium denudatum Wall. (Jadwar, family; Ranuncu-
laceae) is found on the outer ranges of western Himalayas
from Kashmir to Kumaon. It is one of the most important
drugs used in the indigenous system of medicine in India,
especially in Unani Medicine. The roots are reported to be
useful in a variety of ailments such as aconite poisoning,
brain diseases, fungal infection, piles and toothache as an-
algesic and astringent [1–3]. Its use in opium addiction is
mentioned in some classical literature [4,5].
A number of studies have been done on its phytochemical
and pharmacological properties [6–8]. Its de-addiction
property in moderately induced morphine dependence
was first studied and reported by us [9]. The study was fur-
ther extended to explore the suppression of withdrawal
signs by D. denudatum in rats during severely induced
morphine dependence.
Materials and Methods
Animals
Seven weeks old male albino rats of Charles Foster strain
(100–150 g) were used. The rats, purchased from JNMC
Animal House, Aligarh, were housed in groups of eight in
standard cages with free access to solid pellet diet (Gold
Mohar, Lipton-India, Ltd.) and tap water except during
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the time of experiment. The "Animal Observation Room"
was controlled so that the light dark cycle (light period
6.00 am to 6.00 p.m.; 12 hours) and temp. (23 ± 2°C)
were nearly constant. The study was approved by the
JNMC Animal Ethics Committee.
Drugs
Morphine sulphate (Sigma Chemicals Co., USA).
Delphinium denudatum Wall. (D. d). The tuberous roots
of D.d. in the dried form were procured from Dawakhana
Tibbia College, Aligarh Muslim University, Aligarh. These
were identified by comparison for macroscopic and mi-
croscopic characters with authentic specimens of D. d.
kept at the Botanical Survey of India and the Forest Re-
search Institute, Dehradun. Due to the presence of various
alkaloids in roots, the extraction was carried out by mixing
the powdered roots with 1:3 w/v in absolute alcohol by
Soxhlets apparatus for 72 hours. Yield of extract was 7.43
% w/w in terms of dried starting material. It was sticky in
character, pilular, brown and of pleasant smell.
Treatment schedule
The rats were divided into 6 groups of 8 animals each. All
the animals were treated with 0.9% saline, D.d. extract us-
ing distilled water as the dose vehicle and morphine as per
7-d schedule given in Table 1 (see Additional File) [10]:
Group 1: N. Saline 0.9% (1.0 ml/kg, p. o., twice daily)
Group 2: D. d. (350 mg/kg, p. o., twice daily)
Group 3: Morphine (10 – 100 mg/kg, i. p., twice daily)
Group 4: D. d (350 mg/kg, p.o., twice daily) along with
Morphine (10 – 100 mg/kg).
Group 5: D. d. (700 mg/kg, p.o., single dose) 10 h after
the last dose of morphine.
Group 6: D. d (700 mg/kg, p.o., single dose) 10 h prior to
the first dose of morphine.
Technique
The morphine abstinence syndrome, on which the assess-
ment of physical dependence of morphine was based,
consisted of a variety of motor and vegetative signs. The
signs of spontaneous abstinence syndrome were recorded
12 h after the last dose of morphine for 30 min in a clear
perspex acrylic box of 35 ×  22.5 ×  13.75 cm. Similar ob-
servations were also done in D. d. and Saline treated
groups. The 'counted signs' and 'checked signs' were mul-
tiplied with the respective 'weighing factors' Table 2 (see
Additional File) for evaluation of the severity of absti-
nence syndrome using a modified methods of Blasig J, et
al. and Neil & Sparber [11,12].
Statistical analysis
Results are expressed as mean ± SEM. Statistical analysis of
the data was performed using a non-parametric analysis
of variance (ANOVA) and Dunnets Multiple comparison
test followed by Friedman test with post-test. P value <
0.05 was considered significant. All statistical procedures
were performed with GraphPad software version 3.05
(San Diego California USA,  [www.graphpad.com] )
Results
In group 1, which was treated only with saline, there were
occasional episodes of chewing, exploring, digging and
yawning at the time of observation. Group 2, adminis-
tered with D.d. in dose of 350 mg/kg twice daily, also
showed occasional but inconsistent signs namely chew-
ing, exploring, yawning, squeaking on touch which were
comparable to group 1. Group 3 which was given only
morphine in increasing doses (10 – 100 mg/kg) displayed
signs of severe morphine dependence observed 12 hours
after the last dose. These animals showed head shakes,
digging, teeth chattering, jumping, wet-dog shakes, writh-
ing, squeaking on touch, hostility on handling, eye
twitching and lacrimation while there was multifold in-
crease in chewing, exploring, digging and yawning as
compared to groups 1 and 2. In group 4, in which alcohol-
ic extract of D. d. in dose of 350 mg/kg was given along-
with morphine showed reduction in the withdrawal signs
of morphine dependence as observed by lower values of
checked and counted signs when compared to morphine
treated group 3. Animals of group 5, which were adminis-
tered with single dose of alcoholic extract of D. d. (700
mg/kg) 10 h after the last dose of morphine, i.e. 2 h before
the time of observation, showed marked reduction in the
appearance of withdrawal signs of morphine dependence.
The values of counted and checked signs were significant-
ly reduced in all observed parameters as compared to
group 3. In group 6, administration with single dose of al-
coholic extract of D. d. (700 mg/kg) 10 h prior to the first
dose of morphine, caused a reduction in the development
of morphine dependence as compared to group 3. The re-
duction in cumulative scores of counted and checked
signs was maximum in group 5 followed by group 4 and
6 (Table 3 see Additional File). The mean aggregate score
of 12.9 ± 2.5 in morphine-treated animals (group 3) was
reduced to 7.2 ± 1.7, 5.8 ± 1.5 and 10.6 ± 1.9 in the ani-
mals of group 4, group 5 and group 6, respectively (fig 1).
Discussion
The study was conducted to evaluate the ability of D. d. to
suppress the signs of withdrawal in morphine-dependent
rats. In our set up, we could observe only nine counted
signs, viz. chewing, head shakes, exploring, digging, yawn-BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/6
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ing, teeth chattering, jumping, wet dog shakes and writh-
ing, and four checked signs, viz. Squeaking on touch,
hostility on handling, eye twitching and lacrimation out
of all signs mentioned in Table 2. Similar propensity of
withdrawal signs was reported by other workers [10,11],
who also observed that certain signs were more promi-
nent with less dependence and disappear as the degree of
dependence increases, while other signs emerge [12]. Fur-
ther, it has been observed that the intensity of tolerance
and precipitated withdrawal in rodents is a function of the
dosage and the interval of administration of morphine
[13].
Administration of morphine in increasing doses caused
development of severe dependence, which was confirmed
by observing withdrawal signs after 12 h of the last dose
of morphine. A reduction in the severity of the abstinence
syndrome was observed in group 4, 5 and 6, which were
treated with alcoholic extract of D.d. alongwith morphine
in different dose regimens. The maximum reduction in
withdrawal signs was observed in group 5 in which the
drug (D.d.) was given in single dose (700 mg/kg) 2 h prior
to the time of observation or 10 h after the last dose of
morphine. The scores for chewing, exploring, digging,
yawning, teeth chattering, hostility on handling, writhing
and eye twitching were significantly decreased (p < 0.001)
whereas the score of headshakes, Squeaking on touch, wet
dog shakes and jumping fell to zero. In group 4 and 6,
where the drug (D.d) was given in multiple doses (350
mg/kg twice daily ×  7 d) and single dose (700 mg /kg)
once 10 h before the first morphine dose, respectively, the
reduction in withdrawal signs was less as compared to
group 5.
The drug appears to act on sites other than opioid recep-
tors because it neither caused development of dependence
as observed by absence of withdrawal signs in group 2 nor
it ameliorated the signs of abstinence syndrome in group
4 to the extent as it did in group 5. The drug appears to act
centrally independent to opioid receptors. Moreover, the
principal alkaloid of Delphinium genus, methyllycaconi-
tine (MLA), has been reported to have a blocking activity
at alpha 7-type neuronal nicotinic receptor. A series of C-
19 diterpenoid alkaloids purified from Delphinium are
reported as inhibitors of α -bungarotoxin binding to rat
and housefly neuronal membranes [14]. MLA, isolated
from Delphinium seeds, inhibited acetylcholine and ana-
toxin induced whole-cell currents in cultured fetal rat hip-
pocampal neurons, which was concentration dependent,
reversible and voltage dependent [15]. The distribution of
MLA, a non-diterpenoid alkaloid, binding sites in rat
brain has been reported: high density in hippocampus
and hypothalamus, low density in striatum and cerebel-
lum [16]. MLA has also been reported to produce nearly
complete functional blockade of nicotinic receptors locat-
ed at Edinger Westphal neurons in chick. MLA inhibits κ -
bungarotoxin sensitive nicotinic receptor in ciliary gangli-
on. MLA binds most avidly to α -bungarotoxin site in
brain and is 200 fold less potent at muscle nicotinic recep-
tor [17]. The exact sites and mechanism of action of Del-
phinium denudatum needs further evaluation.
The extract seems to have a rapid onset and long duration
of action as evident from the results of group 5 and 6 re-
spectively.
In the light of the above findings, the drug significantly re-
duces the aggregate of scores for all parameters showing
striking attenuation of severe morphine withdrawal syn-
drome. Thus, the drug may prove to be an alternative rem-
edy in morphine de-addiction.
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